Axsome Therapeutics (AXSM) Change in Account Payables (2022 - 2026)
Axsome Therapeutics' Change in Account Payables history spans 5 years, with the latest figure at $41.2 million for Q1 2026.
- On a quarterly basis, Change in Account Payables rose 201.31% to $41.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $21.0 million, a 33.97% decrease, with the full-year FY2025 number at -$6.5 million, down 120.63% from a year prior.
- Change in Account Payables hit $41.2 million in Q1 2026 for Axsome Therapeutics, up from $11.3 million in the prior quarter.
- Over the last five years, Change in Account Payables for AXSM hit a ceiling of $41.2 million in Q1 2026 and a floor of -$37.4 million in Q3 2025.
- Historically, Change in Account Payables has averaged $5.5 million across 5 years, with a median of $7.2 million in 2023.
- Biggest five-year swings in Change in Account Payables: soared 562.5% in 2024 and later plummeted 1383.93% in 2025.
- Tracing AXSM's Change in Account Payables over 5 years: stood at $25.8 million in 2022, then tumbled by 55.04% to $11.6 million in 2023, then plummeted by 33.13% to $7.7 million in 2024, then skyrocketed by 46.05% to $11.3 million in 2025, then surged by 263.97% to $41.2 million in 2026.
- Business Quant data shows Change in Account Payables for AXSM at $41.2 million in Q1 2026, $11.3 million in Q4 2025, and -$37.4 million in Q3 2025.